• Medientyp: E-Artikel
  • Titel: Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy
  • Beteiligte: Borkowetz, Angelika [VerfasserIn]; Renner, Theresa [VerfasserIn]; Platzek, Ivan [VerfasserIn]; Toma, Marieta [VerfasserIn]; Herout, Roman [VerfasserIn]; Baunacke, Martin [VerfasserIn]; Groeben, Christer [VerfasserIn]; Huber, Johannes [VerfasserIn]; Laniado, Michael [VerfasserIn]; Baretton, Gustavo [VerfasserIn]; Froehner, Michael [VerfasserIn]; Zastrow, Stefan [VerfasserIn]; Wirth, Manfred P. [VerfasserIn]
  • Erschienen: Basel : Karger, [2020]
  • Sprache: Englisch
  • DOI: 10.1159/000492495
  • Schlagwörter: Prognose ; Multiparametrische Magnetresonanztomographie ; Prediction ; medicine ; Prostatektomie ; Systematic biopsy ; Previous negative biopsy ; Medizin ; Magnetic resonance imaging/Ultrasound-fusion biopsy ; Multiparametric magnetic resonance imaging ; Prostatakrebs ; Systematische Biopsie ; Vorherige negative Biopsie ; Magnetresonanztomographie/Ultraschallfusionsbiopsie ; Prostatectomy ; Prostate cancer
  • Entstehung:
  • Anmerkungen: Hinweis: Link zum Artikel der zuerst in der Zeitschrift 'Urologia Internationalis' erschienen ist DOI: 10.1159/000492495
  • Beschreibung: Objectives: We compared the transperineal MRI/ultrasoundfusion biopsy (fusPbx) to transrectal systematic biopsy (sys-Pbx) in patients with previously negative biopsy and investigated the prediction of tumour aggressiveness with regard to radical prostatectomy (RP) specimen. Material and Methods: A total of 710 patients underwent multiparametric magnetic resonance imaging (mpMRI), which was evaluated in accordance with Prostate Imaging Reporting and Data System (PI-RADS). The maximum PI-RADS (maxPI-RADS) was defined as the highest PI-RADS of all lesions detected in mpMRI. In case of proven prostate cancer (PCa) and performed RP, tumour grading of the biopsy specimen was compared to that of the RP. Significant PCa (csPCa) was defined according to Epstein criteria. Results: Overall, scPCa was detected in 40% of patients. The detection rate of scPCa was 33% for fusPbx and 25% for sysPbx alone (p < 0.005). Patients with a maxPI-RADS ≥3 and a prostate specific antigen (PSA)-density ≥0.2 ng/mL2 harboured more csPCa than those with a PSA-density < 0.2 ng/mL2 (41% [33/81] vs. 20% [48/248]; p < 0.001). Compared to the RP specimen (n = 140), the concordance of tumour grading was 48% (γ = 0.57), 36% (γ = 0.31) and 54% (γ = 0.6) in fusPbx, sysPbx and comPbx, respectively. Conclusions: The combination of fusPbx and sysPbx outperforms both biopsy modalities in patients with re-biopsy. Additionally, the PSA-density may represent a predictor for csPCa in patients with maxPI-RADS ≥3.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Urheberrechtsschutz